Viridian Therapeutics Inc (VRDN) - Net Assets
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has net assets worth $636.01 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($789.02 Million) and total liabilities ($153.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Viridian Therapeutics Inc (VRDN) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $636.01 Million |
| % of Total Assets | 80.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | 284.71% |
| 10-Year Change | N/A |
| Growth Volatility | 195.45 |
Viridian Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See VRDN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Viridian Therapeutics Inc from 2012 to 2025. For live valuation and market cap data, see Viridian Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $722.17 Million | +7.52% |
| 2024-12-31 | $671.64 Million | +51.95% |
| 2023-12-31 | $442.02 Million | +11.89% |
| 2022-12-31 | $395.06 Million | +110.46% |
| 2021-12-31 | $187.72 Million | +56.38% |
| 2020-12-31 | $120.04 Million | +661.95% |
| 2019-12-31 | $15.75 Million | -69.32% |
| 2018-12-31 | $51.34 Million | +33.33% |
| 2017-12-31 | $38.51 Million | +11912.88% |
| 2016-12-31 | $-326.00K | -103.13% |
| 2015-12-31 | $10.41 Million | +73.76% |
| 2014-12-31 | $5.99 Million | +195.63% |
| 2013-12-31 | $2.03 Million | +109.45% |
| 2012-12-31 | $-21.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viridian Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 131701563400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.02 Million | 0.14% |
| Other Comprehensive Income | $447.00K | 0.06% |
| Other Components | $2.06 Billion | 285.14% |
| Total Equity | $722.17 Million | 100.00% |
Viridian Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Viridian Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TX Group AG
SW:TXGN
|
$1.71 Billion |
|
Suzhou Oriental Semiconductor Co. Ltd. A
SHG:688261
|
$1.71 Billion |
|
SALZGITTER UNSP.ADR 1/10
F:SZGA
|
$1.71 Billion |
|
Guangzhou Zhiguang Electric Co Ltd
SHE:002169
|
$1.71 Billion |
|
JiLin Sino-Microelectronics Co Ltd
SHG:600360
|
$1.71 Billion |
|
Companhia Siderurgica Nacional ADR
NYSE:SID
|
$1.71 Billion |
|
Choice International Limited
NSE:CHOICEIN
|
$1.71 Billion |
|
Meta Financial Group Inc
NASDAQ:CASH
|
$1.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viridian Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 671,639,000 to 722,167,000, a change of 50,528,000 (7.5%).
- Net loss of 342,601,000 reduced equity.
- Share repurchases of 1,119,000 reduced equity.
- New share issuances of 352,197,000 increased equity.
- Other comprehensive income increased equity by 457,000.
- Other factors increased equity by 41,594,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-342.60 Million | -47.44% |
| Share Repurchases | $1.12 Million | -0.15% |
| Share Issuances | $352.20 Million | +48.77% |
| Other Comprehensive Income | $457.00K | +0.06% |
| Other Changes | $41.59 Million | +5.76% |
| Total Change | $- | 7.52% |
Book Value vs Market Value Analysis
This analysis compares Viridian Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-115.23 | $16.71 | x |
| 2013-12-31 | $10.77 | $16.71 | x |
| 2014-12-31 | $39.84 | $16.71 | x |
| 2015-12-31 | $19.30 | $16.71 | x |
| 2016-12-31 | $-0.45 | $16.71 | x |
| 2017-12-31 | $30.02 | $16.71 | x |
| 2018-12-31 | $26.02 | $16.71 | x |
| 2019-12-31 | $7.54 | $16.71 | x |
| 2020-12-31 | $33.75 | $16.71 | x |
| 2021-12-31 | $15.75 | $16.71 | x |
| 2022-12-31 | $12.31 | $16.71 | x |
| 2023-12-31 | $9.88 | $16.71 | x |
| 2024-12-31 | $9.89 | $16.71 | x |
| 2025-12-31 | $8.52 | $16.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viridian Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -483.57%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.25x
- Recent ROE (-47.44%) is above the historical average (-75.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -163.67% | 1.58x | 0.00x | $-5.07 Million |
| 2013 | -106.57% | -50.03% | 1.18x | 1.81x | $-2.36 Million |
| 2014 | -131.70% | -182.64% | 0.53x | 1.35x | $-8.49 Million |
| 2015 | -108.82% | -446.34% | 0.20x | 1.24x | $-12.37 Million |
| 2016 | 0.00% | -379.80% | 0.78x | 0.00x | $-12.64 Million |
| 2017 | -68.84% | -662.30% | 0.08x | 1.36x | $-30.36 Million |
| 2018 | -63.69% | -389.97% | 0.13x | 1.29x | $-37.84 Million |
| 2019 | -265.79% | -938.65% | 0.15x | 1.92x | $-43.45 Million |
| 2020 | -92.23% | -10544.29% | 0.01x | 1.09x | $-122.72 Million |
| 2021 | -42.30% | -2680.16% | 0.01x | 1.09x | $-98.18 Million |
| 2022 | -32.87% | -7329.23% | 0.00x | 1.10x | $-169.38 Million |
| 2023 | -53.78% | -75711.46% | 0.00x | 1.11x | $-281.94 Million |
| 2024 | -40.19% | -89387.09% | 0.00x | 1.11x | $-337.11 Million |
| 2025 | -47.44% | -483.57% | 0.08x | 1.25x | $-414.82 Million |
Industry Comparison
This section compares Viridian Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viridian Therapeutics Inc (VRDN) | $636.01 Million | 0.00% | 0.24x | $1.71 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more